2 Stocks Down 8% or More That Are Screaming Buys Right Now
2026-09-04 14:30
•Prosper Junior Bakiny •The Motley Fool
•••••• ••• Axe Cap view
Two Slumping Global Stocks Worth Watching from Afar
Intuitive Surgical and Novo Nordisk face tough years but hold long-term promise rooted in innovation.
Intuitive Surgical has had a rough ride, down over 30% this year. Yet, their da Vinci 5 surgical robot packs tech that could meaningfully expand its market reach and recurring revenue from higher-margin accessories. More adoption means better margins and a possibly undervalued entry point. Novo Nordisk lost ground to Eli Lilly in the GLP-1 weight-loss race, but its pipeline drugs show impressive early results suggesting a potential market share rebound. For South African investors, these names don’t map directly to local counters, but the US-dollar weakness relative to the rand (USD/ZAR) is a consideration when converting gains or losses. A softer dollar might inflate returns in rand terms should these stocks recover. If USD/ZAR strengthens instead, that could dampen returns from dollar assets. Both plays are about patience and conviction, not quick wins. this is just our opinion and not financial advice
I would watch USD/ZAR closely and consider small positions in these stocks if you have a penchant for emerging tech in healthcare and pharma innovation, but only allocate capital you can afford to leave untouched for years. Avoid chasing price dips without clear catalysts.
- ISRG
- NVO
- USD/ZAR
- USD/ZAR moves against you, lowering rand returns
- Pipeline drugs fail in late-stage trials or fail to gain market share
4/10
The article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.
Our take is based on reporting first published by The Motley Fool.